Log in

NASDAQ:AMRNAmarin Stock Price, Forecast & News

$6.77
+0.29 (+4.48 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.47
Now: $6.77
$6.80
50-Day Range
$6.42
MA: $6.74
$7.14
52-Week Range
$3.95
Now: $6.77
$26.12
Volume6.69 million shs
Average Volume4.87 million shs
Market Capitalization$2.61 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More
Amarin logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$429.76 million
Book Value$1.63 per share

Profitability

Net Income$-22,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.61 billion
Next Earnings Date8/4/2020 (Confirmed)
OptionableOptionable
$6.77
+0.29 (+4.48 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amarin (NASDAQ:AMRN) Frequently Asked Questions

How has Amarin's stock been impacted by COVID-19 (Coronavirus)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMRN stock has decreased by 46.1% and is now trading at $6.77.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Amarin?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amarin
.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company had revenue of $155 million for the quarter, compared to analysts' expectations of $150.06 million. Amarin had a negative return on equity of 4.05% and a negative net margin of 3.67%. The company's revenue for the quarter was up 111.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) earnings per share.
View Amarin's earnings history
.

What price target have analysts set for AMRN?

13 brokers have issued twelve-month target prices for Amarin's stock. Their forecasts range from $4.00 to $51.00. On average, they anticipate Amarin's share price to reach $17.23 in the next twelve months. This suggests a possible upside of 154.5% from the stock's current price.
View analysts' price targets for Amarin
.

Has Amarin been receiving favorable news coverage?

Headlines about AMRN stock have trended somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amarin earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about Amarin
.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), Alibaba Group (BABA), Gilead Sciences (GILD), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.16%), Frontier Capital Management Co. LLC (0.14%), Rhenman & Partners Asset Management AB (0.14%), Raymond James & Associates (0.10%), Spring Creek Investment Management LLC (0.06%) and Westside Investment Management Inc. (0.05%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin
.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Vigilare Wealth Management, and Integrated Wealth Concepts LLC. Company insiders that have sold Amarin company stock in the last year include John F Thero, and Lars Ekman.
View insider buying and selling activity for Amarin
.

Which institutional investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Spring Creek Investment Management LLC, Westside Investment Management Inc., Kornitzer Capital Management Inc. KS, Premier Asset Management LLC, Raymond James & Associates, Chartwell Investment Partners LLC, and Altium Wealth Management LLC.
View insider buying and selling activity for Amarin
.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $6.77.

How big of a company is Amarin?

Amarin has a market capitalization of $2.61 billion and generates $429.76 million in revenue each year. The biopharmaceutical company earns $-22,650,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.